|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table S3. Associations of week 48 clinical response with baseline and week 16 biomarker levels.** | | | | | | | | | | |
|  |  | **Week 48 clinical response, fold (R/NR)** † | | | | | | | | |
| **Biomarker \*** |  | **Placebo** | | | |  | **Golimumab** | | | |
|  | **No Flare** | **JIA-ACR30** | **Remission** | **Inactive Disease** |  | **No Flare** | **JIA-ACR30** | **Remission** | **Inactive Disease** |
| ***Week 0 levels*** |  |  |  |  |  |  |  |  |  |  |
| C-reactive protein |  | **-3.85** | **-4.94** | **-7.41** | **-4.07** |  | 1.37 | 1.56 | -2.49 | 1.06 |
| Interleukin-6 |  | **-2.74** | **-2.98** | **-5.71** | **-3.46** |  | 1.44 | 1.69 | -1.31 | -1.08 |
| Serum amyloid A |  | **-3.21** | **-3.60** | **-5.29** | **-3.19** |  | -1.40 | -1.19 | -1.01 | -1.20 |
| Fibroblast Growth Factor, basic |  | -1.49 | -1.33 | **-3.79** | **-2.05** |  | 1.11 | -1.01 | 1.33 | -1.01 |
| Interleukin-8 |  | -1.08 | -1.07 | -1.04 | -1.33 |  | -1.09 | 1.06 | -1.17 | -1.12 |
| Interferon-induced protein-10 |  | -1.39 | -1.43 | -1.22 | -1.27 |  | -1.00 | 1.04 | -1.59 | -1.58 |
| Vascular Endothelial Growth Factor |  | **-1.69** | **-1.61** | **-2.21** | **-1.62** |  | 1.08 | 1.24 | 1.04 | 1.02 |
| Erythrocyte Sedimentation Rate |  | **-1.45** | **-1.47** | **-1.84** | **-1.58** |  | 1.15 | 1.44 | -2.60 | 1.14 |
| Blood Neutrophils (density) |  | -1.17 | -1.19 | **-1.39** | **-1.27** |  | -1.05 | -1.03 | 1.05 | -1.02 |
| Blood Leukocytes (density) |  | -1.11 | -1.13 | -1.22 | -1.15 |  | -1.01 | 1.02 | 1.05 | 1.01 |
| ***Week 16 levels*** |  |  |  |  |  |  |  |  |  |  |
| C-reactive protein |  | -2.46 | -2.41 | -4.08 | **-3.80** |  | -1.01 | 1.04 | -3.63 | -2.03 |
| Interleukin-6 |  | **-2.13** | **-2.24** | **-2.74** | **-2.91** |  | -1.04 | -1.05 | **-3.50** | **-2.75** |
| Serum amyloid A |  | -1.48 | -1.41 | -2.27 | -1.78 |  | 1.06 | 1.15 | -1.20 | -1.64 |
| Fibroblast Growth Factor, basic |  | -1.02 | -1.03 | -2.09 | 1.09 |  | 1.46 | 1.20 | -1.06 | 1.37 |
| Interleukin-8 |  | **1.30** | 1.27 | -1.01 | 1.15 |  | 1.22 | 1.28 | -1.31 | 1.22 |
| Interferon-induced protein-10 |  | -1.44 | -1.44 | -1.79 | -1.48 |  | -1.09 | -1.10 | -1.34 | -1.30 |
| Vascular Endothelial Growth Factor |  | **-1.50** | -1.43 | -1.69 | -1.42 |  | -1.21 | -1.12 | -1.30 | -1.36 |
| Erythrocyte Sedimentation Rate |  | **-1.28** | **-1.33** | **-1.44** | **-1.24** |  | -1.18 | 1.01 | **-2.00** | **-1.24** |
| Blood Neutrophils (density) |  | -1.10 | -1.09 | -1.31 | -1.10 |  | **-1.23** | -1.20 | -1.00 | -1.13 |
| Blood Leukocytes (density) |  | -1.04 | -1.03 | -1.18 | -1.05 |  | -1.08 | -1.09 | 1.09 | -1.04 |
| \* Baseline and week 16 levels of indicated serum analyte or hematology parameter reported for those with p<0.05 for 'Yes' vs. 'No' for at least one of the week 48 response variables.  † Fold for geometric mean of 'Yes' over geometric mean of 'No', for indicated biomarkers, reported for indicated week 48 response variable; values bolded and shaded when p<0.05.  R = Responder. NR = Nonresponder. JIA-ACR30 = ≥30% improvement in Juvenile Idiopathic Arthritis-American College of Rheumatology response criteria | | | | | | | | | | |